Mari Iwata, Mika Maezawa, Koumi Miyasaka, Sakiko Hirofuji, Takaaki Suzuki, Satoshi Nakao, Hirofumi Tamaki, Nanaka Ichihara, Yuka Nokura, Mayuko Masuta, Hiroaki Uranishi, Yuri Nishibata, Kazuhiro Iguchi, Mitsuhiro Nakamura
In this study, information on injectable anticancer drug use and additional fee for enhanced collaboration (AEC) and additional fee for specific drug management guidance 2 (ASD2) claims from the NDB Open Data Japan (NODJ) dataset and the number of patients with cancer according to sex and age from the National Cancer Registry (NCR) dataset were integrated and evaluated to determine the current status and challenges in pharmacist interventions for patients receiving cancer treatment. The NODJ data, including receipt data billed from 2020 to 2021, were obtained from the Ministry of Health, Labour and Welfare website...
2024: Journal of Pharmaceutical Policy and Practice